{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    5,
    8,
    12,
    16,
    17,
    28,
    106
  ],
  "modelUsed": "gemini-3-flash-preview",
  "advanced": {
    "studyAmendments": [
      {
        "id": "amend_1",
        "number": "INT-6",
        "name": "Amendment INT-6",
        "scope": {
          "id": "d1494451-193f-466b-b29e-70914ac93dc6",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "161769e1-ce89-4d24-b17d-4b03a0e777a6",
          "code": {
            "id": "0ae552fa-c79a-4759-93a7-bfe61809ed84",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "14243dc9-8895-40df-a51a-5bf405ca83b0",
            "type": {
              "id": "d7bd013c-443b-4592-a6b3-64dfbaf2b8ec",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "The primary reason for the amendment is to decrease the number of primary composite events required for the interim analysis from 540 to 405. In addition, 2 new secondary endpoints have been added and secondary endpoints have been reordered.",
        "effectiveDate": "2017-09-06",
        "reasonIds": [
          "ar_1_1",
          "ar_1_2"
        ],
        "previousVersion": "INT-5",
        "newVersion": "INT-6"
      },
      {
        "id": "amend_2",
        "number": "INT-5",
        "name": "Amendment INT-5",
        "scope": {
          "id": "8e8ad511-2acd-47f9-a890-03924b3a6868",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "002f4079-b526-445a-9b52-bec076ab0de3",
          "code": {
            "id": "82478bff-7194-4b46-baaf-837ba76a85b9",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "ca7ca5f9-12f9-4f09-b40e-690f71b817c6",
            "type": {
              "id": "1a41709a-1280-4acc-bc81-660ff81a927d",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "The primary reason to amend the study protocol is to include new safety information and guidance regarding subject management surrounding the event of lower extremity amputations.",
        "effectiveDate": "2016-05-06",
        "reasonIds": [
          "ar_2_1",
          "ar_2_2"
        ],
        "previousVersion": "INT-4",
        "newVersion": "INT-5"
      },
      {
        "id": "amend_3",
        "number": "INT-4",
        "name": "Amendment INT-4",
        "scope": {
          "id": "b6929c85-4a2c-4660-92b5-5a7cf815810b",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "e5a055ab-dca9-49d2-a953-b811dcee46ce",
          "code": {
            "id": "32bad513-f3f0-44a8-8a39-4ee7f24746e8",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "6e7f3daa-f2bd-4556-8894-1725be8e3eb2",
            "type": {
              "id": "d1289dc7-05df-4549-aeac-cfd2225ffac6",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "To provide further clarifications regarding ACEi or ARB therapy, study design rationale, and drug accountability.",
        "effectiveDate": "2016-01-19",
        "reasonIds": [
          "ar_3_1",
          "ar_3_2"
        ],
        "previousVersion": "INT-3",
        "newVersion": "INT-4"
      },
      {
        "id": "amend_4",
        "number": "INT-3",
        "name": "Amendment INT-3",
        "scope": {
          "id": "b5799a20-4d36-4029-8a93-ec3e9d07c807",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "2aa2db20-27af-46e6-b6f3-2142ac799082",
          "code": {
            "id": "ee26f8dc-00ba-44cd-8974-9175f01c921c",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "7ecdc586-bab7-4e72-a195-d5ef42905ee6",
            "type": {
              "id": "c521478c-5105-413e-a90f-7b62a916ca80",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "The overall reason for the amendment was to provide further clarifications to the protocol text.",
        "effectiveDate": "2015-09-29",
        "reasonIds": [
          "ar_4_1"
        ],
        "previousVersion": "INT-2",
        "newVersion": "INT-3"
      },
      {
        "id": "amend_5",
        "number": "INT-2",
        "name": "Amendment INT-2",
        "scope": {
          "id": "02c832cd-2067-4c4b-858f-126e858c7dcc",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "66f59020-a7db-4f55-ae45-436d94be1e6c",
          "code": {
            "id": "27e78849-dabf-4b0f-846f-b7b8d5a8070c",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "cd92eda3-3d0e-491a-8294-056d8590d384",
            "type": {
              "id": "635259d4-12ce-4a28-9ae5-bcd353d8bf6b",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "To revise inclusion criteria to allow patients with higher baseline HbA1c values who may benefit from the study treatment to participate in the study. In addition, changes to the prescreening assessment are intended to allow a wider range of measures to prescreen subjects for albuminuria/proteinuria, as well as to extend the duration of the prescreening assessment of the study.",
        "effectiveDate": "2015-02-03",
        "reasonIds": [
          "ar_5_1",
          "ar_5_2"
        ],
        "previousVersion": "INT-1",
        "newVersion": "INT-2"
      },
      {
        "id": "amend_6",
        "number": "INT-1",
        "name": "Amendment INT-1",
        "scope": {
          "id": "97525db4-4e11-491e-910f-cb1063445921",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "74e778be-4c4f-44ae-bd28-1a7de3abff55",
          "code": {
            "id": "2295edff-ac18-46ff-99c6-20a23965e129",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "3ed51040-79b5-4719-bae4-a7e436d2cde9",
            "type": {
              "id": "ccb143cd-5be4-4540-975f-1e47e9cefead",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "The primary reason for the amendment to the protocol is to reflect recommendations from the United States (US) Food and Drug Administration (FDA) for study 28431754DNE3001.",
        "effectiveDate": "2014-06-12",
        "reasonIds": [
          "ar_6_1",
          "ar_6_2"
        ],
        "previousVersion": "Original Protocol",
        "newVersion": "INT-1"
      }
    ],
    "amendmentReasons": [
      {
        "id": "ar_1_1",
        "code": "SCIENTIFIC",
        "description": "Scientific",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_1_2",
        "code": "OPERATIONAL",
        "description": "Operational",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_2_1",
        "code": "SAFETY",
        "description": "Safety",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_2_2",
        "code": "REGULATORY",
        "description": "Regulatory",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_3_1",
        "code": "ADMINISTRATIVE",
        "description": "Administrative",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_3_2",
        "code": "OPERATIONAL",
        "description": "Operational",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_4_1",
        "code": "ADMINISTRATIVE",
        "description": "Administrative",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_5_1",
        "code": "SCIENTIFIC",
        "description": "Scientific",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_5_2",
        "code": "OPERATIONAL",
        "description": "Operational",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_6_1",
        "code": "REGULATORY",
        "description": "Regulatory",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_6_2",
        "code": "SCIENTIFIC",
        "description": "Scientific",
        "instanceType": "AmendmentReason"
      }
    ],
    "countries": [
      {
        "id": "country_1",
        "name": "United States",
        "instanceType": "Country",
        "code": "US"
      }
    ],
    "studySites": [],
    "summary": {
      "amendmentCount": 6,
      "countryCount": 1,
      "siteCount": 0
    },
    "geographicScope": {
      "id": "geo_1",
      "name": "Study Geographic Scope",
      "scopeType": "Global",
      "instanceType": "GeographicScope",
      "countryIds": [
        "country_1"
      ],
      "regions": [
        "North America",
        "Europe"
      ]
    }
  },
  "rawResponse": {
    "amendments": [
      {
        "number": "INT-6",
        "effectiveDate": "2017-09-06",
        "summary": "The primary reason for the amendment is to decrease the number of primary composite events required for the interim analysis from 540 to 405. In addition, 2 new secondary endpoints have been added and secondary endpoints have been reordered.",
        "previousVersion": "INT-5",
        "newVersion": "INT-6",
        "reasons": [
          "Scientific",
          "Operational"
        ]
      },
      {
        "number": "INT-5",
        "effectiveDate": "2016-05-06",
        "summary": "The primary reason to amend the study protocol is to include new safety information and guidance regarding subject management surrounding the event of lower extremity amputations.",
        "previousVersion": "INT-4",
        "newVersion": "INT-5",
        "reasons": [
          "Safety",
          "Regulatory"
        ]
      },
      {
        "number": "INT-4",
        "effectiveDate": "2016-01-19",
        "summary": "To provide further clarifications regarding ACEi or ARB therapy, study design rationale, and drug accountability.",
        "previousVersion": "INT-3",
        "newVersion": "INT-4",
        "reasons": [
          "Administrative",
          "Operational"
        ]
      },
      {
        "number": "INT-3",
        "effectiveDate": "2015-09-29",
        "summary": "The overall reason for the amendment was to provide further clarifications to the protocol text.",
        "previousVersion": "INT-2",
        "newVersion": "INT-3",
        "reasons": [
          "Administrative"
        ]
      },
      {
        "number": "INT-2",
        "effectiveDate": "2015-02-03",
        "summary": "To revise inclusion criteria to allow patients with higher baseline HbA1c values who may benefit from the study treatment to participate in the study. In addition, changes to the prescreening assessment are intended to allow a wider range of measures to prescreen subjects for albuminuria/proteinuria, as well as to extend the duration of the prescreening assessment of the study.",
        "previousVersion": "INT-1",
        "newVersion": "INT-2",
        "reasons": [
          "Scientific",
          "Operational"
        ]
      },
      {
        "number": "INT-1",
        "effectiveDate": "2014-06-12",
        "summary": "The primary reason for the amendment to the protocol is to reflect recommendations from the United States (US) Food and Drug Administration (FDA) for study 28431754DNE3001.",
        "previousVersion": "Original Protocol",
        "newVersion": "INT-1",
        "reasons": [
          "Regulatory",
          "Scientific"
        ]
      }
    ],
    "geographicScope": {
      "type": "Global",
      "countries": [
        {
          "name": "United States",
          "code": "US"
        }
      ],
      "regions": [
        "North America",
        "Europe"
      ],
      "plannedSites": null
    },
    "sites": []
  }
}